| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| TLXTelix Pharmaceuticals Limited | 2.49B | 7.43 | 53.07 | 55.85% | 3.98% | 15.63% | 0.36% | 1.02 |
| EXELExelixis, Inc. | 12.18B | 45.44 | 25.82 | 18.49% | 29.63% | 31.37% | 5.2% | 0.09 |
| BBOTBridgeBio Oncology Therapeutics Inc. | 919.87M | 11.50 | 25 | -25.73% | ||||
| INBXInhibrx Biosciences, Inc. | 1.04B | 71.80 | 0.62 | -88.89% | -110.78% | -421.09% | 0.06 | |
| NUVBNuvation Bio Inc. | 2.1B | 6.14 | -2.91 | -8.13% | -66.74% | 0.02 | ||
| RLAYRelay Therapeutics, Inc. | 1.32B | 7.63 | -3.23 | -60.83% | -26.71% | -48.97% | 0.06 | |
| ORICORIC Pharmaceuticals, Inc. | 1.12B | 11.52 | -6.30 | -33.24% | 0.01 | |||
| ZLABZai Lab Limited | 2.09B | 18.82 | -7.24 | 49.59% | -46.83% | -27.21% | 0.18 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 45.73M | 0 | 5M | 0 |
| Revenue Growth % | - | - | - | -1% | - | -1% |
| Cost of Goods Sold | 1.48M | 1.51M | 0 | 2.04M | 0 | 1.87M |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | -1.48M | -1.51M | 45.73M | -2.04M | 5M | -1.87M |
| Gross Margin % | - | - | 1% | - | 1% | - |
| Gross Profit Growth % | - | -0.02% | 31.31% | -1.04% | 3.45% | -1.37% |
| Operating Expenses | 17.64M | 24.59M | 54.37M | 58.91M | 72.55M | 53.02M |
| OpEx % of Revenue | - | - | 1.19% | - | 14.52% | - |
| Selling, General & Admin | 4.3M | 5.56M | 12.45M | 13.04M | 15.29M | 8.09M |
| SG&A % of Revenue | - | - | 0.27% | - | 3.06% | - |
| Research & Development | 13.34M | 19.04M | 42.1M | 54.49M | 58.15M | 44.94M |
| R&D % of Revenue | - | - | 0.92% | - | 11.64% | - |
| Other Operating Expenses | 0 | 0 | -183K | -8.62M | -890K | 0 |
| Operating Income | -19.12M | -26.1M | -8.65M | -67.27M | -67.55M | -54.9M |
| Operating Margin % | - | - | -0.19% | - | -13.52% | - |
| Operating Income Growth % | - | -0.37% | 0.67% | -6.78% | -0% | 0.19% |
| EBITDA | -17.64M | -24.59M | -6.82M | -66.32M | -65.33M | -53.02M |
| EBITDA Margin % | - | - | -0.15% | - | -13.08% | - |
| EBITDA Growth % | - | -0.39% | 0.72% | -8.73% | 0.01% | 0.19% |
| D&A (Non-Cash Add-back) | 1.48M | 1.51M | 1.83M | 951K | 2.22M | 1.87M |
| EBIT | -17.36M | -61.48M | -55.41M | -58.36M | -103.44M | -49.95M |
| Net Interest Income | -443.28K | -1.72M | -1.31M | 117K | -729K | -1.94M |
| Interest Income | 22.86K | 24.05K | 32.04K | 550K | 61.95K | 0 |
| Interest Expense | 466.14K | 1.75M | 1.34M | 433K | 791K | 1.94M |
| Other Income/Expense | 1.29M | -37.28M | -48.03M | 8.48M | -36.68M | 3M |
| Pretax Income | -17.83M | -63.38M | -56.68M | -58.79M | -104.23M | -51.9M |
| Pretax Margin % | - | - | -1.24% | - | -20.86% | - |
| Income Tax | 0 | 0 | 0 | 0 | 643K | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1.01% | 1% |
| Net Income | -17.83M | -63.38M | -56.68M | -58.79M | -104.87M | -51.9M |
| Net Margin % | - | - | -1.24% | - | -20.99% | - |
| Net Income Growth % | - | -2.55% | 0.11% | -0.04% | -0.78% | 0.51% |
| Net Income (Continuing) | -17.83M | -63.38M | -56.68M | -58.79M | -104.87M | -51.9M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.10 | -7.62 | -6.66 | -6.93 | -15.42 | -4.89 |
| EPS Growth % | - | -2.63% | 0.13% | -0.04% | -1.23% | 0.68% |
| EPS (Basic) | -2.10 | -7.62 | -6.66 | -6.93 | -15.42 | -4.89 |
| Diluted Shares Outstanding | 8.48M | 8.48M | 8.48M | 8.48M | 6.8M | 10.64M |
| Basic Shares Outstanding | 8.48M | 8.48M | 8.48M | 8.48M | 6.8M | 10.64M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 6.43M | 28.59M | 124.54M | 66.3M | 101.19M | 64.06M |
| Cash & Short-Term Investments | 6.02M | 24.5M | 117.94M | 64.05M | 98.5M | 60.91M |
| Cash Only | 6.02M | 24.21M | 64.13M | 42.76M | 91.49M | 60.9M |
| Short-Term Investments | 0 | 241K | 53.81M | 21.29M | 7.01M | 7K |
| Accounts Receivable | 91.59K | 394.05K | 1.93M | 346K | 359K | 1.17M |
| Days Sales Outstanding | - | - | 15.41 | - | 26.23 | - |
| Inventory | 0 | 0 | 0 | -3 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 324.45K | 2.82M | 0 | 3 | 0 | 0 |
| Total Non-Current Assets | 4.37M | 8.15M | 7.14M | 6.29M | 28.99M | 7.21M |
| Property, Plant & Equipment | 3.34M | 6.59M | 6.59M | 5.88M | 3.8M | 2.71M |
| Fixed Asset Turnover | - | - | 6.94x | - | 1.31x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 11K | 97K | 89K | 63K | 40K |
| Long-Term Investments | 81.25K | 0 | 0 | 0 | 24.85M | 4.16M |
| Other Non-Current Assets | 947.36K | 1.48M | 455K | 327K | 282K | 304K |
| Total Assets | 10.8M | 36.74M | 131.69M | 72.59M | 130.19M | 71.27M |
| Asset Turnover | - | - | 0.35x | - | 0.04x | - |
| Asset Growth % | - | 2.4% | 2.58% | -0.45% | 0.79% | -0.45% |
| Total Current Liabilities | 20.32M | 87.99M | 17.5M | 312.65M | 50.32M | 45.36M |
| Accounts Payable | 5.26M | 1.53M | 2.98M | 13.1M | 14.35M | 10.15M |
| Days Payables Outstanding | 1.3K | 369.54 | - | 2.35K | - | 1.98K |
| Short-Term Debt | 10.92M | 82.99M | 10.46M | 4.31M | 30.36M | 26.33M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 1000K | 0 | 1000K |
| Other Current Liabilities | 4.14M | 3.47M | 0 | 290.11M | 1.08M | -3.06M |
| Current Ratio | 0.32x | 0.32x | 7.12x | 0.21x | 2.01x | 1.41x |
| Quick Ratio | 0.32x | 0.32x | 7.12x | 0.21x | 2.01x | 1.41x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 59.86M | 80.31M | 299.62M | 1.24M | 469K | 425K |
| Long-Term Debt | 634.25K | 81.43M | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 1.9M | 2.05M | 1.24M | 469K | 425K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 59.22M | -1.12M | 297.56M | 0 | 0 | 0 |
| Total Liabilities | 80.18M | 168.3M | 317.11M | 313.89M | 50.79M | 45.78M |
| Total Debt | 11.95M | 10.98M | 13.35M | 6.54M | 31.55M | 27.23M |
| Net Debt | 5.93M | -13.22M | -50.79M | -36.21M | -59.94M | -33.68M |
| Debt / Equity | - | - | - | - | 0.40x | 1.07x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | -41.01x | -14.94x | -6.46x | -155.36x | -85.40x | -28.22x |
| Total Equity | -69.38M | -131.56M | -185.43M | -241.29M | 79.4M | 25.48M |
| Equity Growth % | - | -0.9% | -0.41% | -0.3% | 1.33% | -0.68% |
| Book Value per Share | -8.18 | -15.51 | -21.87 | -28.45 | 11.67 | 2.39 |
| Total Shareholders' Equity | -69.38M | -131.56M | -185.43M | -241.29M | 79.4M | 25.48M |
| Common Stock | 2.44K | 2.6K | 4K | 4K | 11K | 11K |
| Retained Earnings | -86.62M | -159.15M | -209.43M | -268.22M | -373.09M | -429.32M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 17.24M | 27.59M | -1M | 9.53M | -4.24M | -4.54M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -14.92M | -34.59M | -3.03M | -43.22M | -56.65M | -51.82M |
| Operating CF Margin % | - | - | -0.07% | - | -11.34% | - |
| Operating CF Growth % | - | -1.32% | 0.91% | -13.25% | -0.31% | 0.09% |
| Net Income | -17.83M | -63.38M | -56.68M | -58.79M | -104.87M | -51.87M |
| Depreciation & Amortization | 1.48M | 1.54M | 1.83M | 2.04M | 2.22M | 1.87M |
| Stock-Based Compensation | 0 | 2.27M | 3.39M | 6.08M | 4.33M | 2.45M |
| Deferred Taxes | 0 | 0 | -67K | -1.04M | 0 | 0 |
| Other Non-Cash Items | -1.59M | 36.28M | 48.25M | -6.76M | 39.9M | 1.27M |
| Working Capital Changes | 3.02M | -11.31M | 250K | 15.25M | 1.77M | -5.54M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 481.92K | -3.86M | 600K | 10.12M | 1.25M | -4.2M |
| Cash from Investing | -184.52K | -1.61M | -54.86M | 28.38M | -10.95M | 28.07M |
| Capital Expenditures | -184.95K | -1.62M | -1.12M | -1.27M | -200K | -170K |
| CapEx % of Revenue | - | - | 0.02% | - | 0.04% | - |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 134K | 569K | 53.6K | 734K |
| Cash from Financing | 16.22M | 53.89M | 97.2M | -6.78M | 116.24M | -6.58M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 16.22M | 57.7M | -1.19M | -292K | -602K | -1.87M |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -15.11M | -36.22M | -4.15M | -44.49M | -56.85M | -51.99M |
| FCF Margin % | - | - | -0.09% | - | -11.38% | - |
| FCF Growth % | - | -1.4% | 0.89% | -9.71% | -0.28% | 0.09% |
| FCF per Share | -1.78 | -4.27 | -0.49 | -5.25 | -8.36 | -4.89 |
| FCF Conversion (FCF/Net Income) | 0.84x | 0.55x | 0.05x | 0.74x | 0.54x | 1.00x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | - | -132.07% | -98.95% |
| Return on Invested Capital (ROIC) | - | - | - | - | -260.36% | -730.77% |
| Gross Margin | - | - | 100% | - | 100.09% | - |
| Net Margin | - | - | -123.95% | - | -2099.25% | - |
| Debt / Equity | - | - | - | - | 0.40x | 1.07x |
| Interest Coverage | -41.01x | -14.94x | -6.46x | -155.36x | -85.40x | -28.22x |
| FCF Conversion | 0.84x | 0.55x | 0.05x | 0.74x | 0.54x | 1.00x |
| Revenue Growth | - | - | - | -100% | - | -100% |
Adlai Nortye Ltd. (ANL) reported $6.5M in revenue for fiscal year 2024.
Adlai Nortye Ltd. (ANL) saw revenue decline by 100.0% over the past year.
Adlai Nortye Ltd. (ANL) reported a net loss of $54.1M for fiscal year 2024.
Adlai Nortye Ltd. (ANL) has a return on equity (ROE) of -99.0%. Negative ROE indicates the company is unprofitable.
Adlai Nortye Ltd. (ANL) had negative free cash flow of $66.9M in fiscal year 2024, likely due to heavy capital investments.